Hyperactive platelets cause multi-organ failure in COVID-19 patients: Aspirin may be the answer

A new study says changes in blood platelets triggered by COVID-19 may contribute to the onset of heart attacks, strokes and other serious complications in some patients.

By: Jahnavi Sarma | | Updated: July 2, 2020 6:37 am

In test tube studies, the researchers found that pre-treating platelets from SARS-CoV-2 infected patients with aspirin did prevent this hyperactivity.

The COVID-19 pandemic causes severe complications in some patients including blood clotting and multi-organ failure. Patients with underlying conditions like diabetes, obesity or high blood pressure are at a higher risk of these complications. Now, according to researchers at the University of Utah, changes in blood platelets triggered by COVID-19 may contribute to the onset of heart attacks, strokes, and other serious complications in some patients who have the disease. The researchers found that inflammatory proteins produced during infection significantly alter the function of platelets. This makes them “hyperactive” and more prone to form dangerous and potentially deadly blood clots. Also Read - Maharashtra records over 10,000 new coronavirus cases, highest since October

Researchers say better understanding of the underlying causes of these changes may possibly lead to treatments that prevent them from happening in COVID-19 patients. This study titled, “Platelet Gene Expression and Function in COVID-19 Patients,” was funded by the National Institutes of Health, the University of Utah Health 3i Initiative, and the American Heart Foundation and it appears in Blood, an American Society of Hematology journal. According to researchers, this is an important piece of the jigsaw puzzle that is COVID-19. They found that inflammation and systemic changes, due to the infection, are influencing how platelets function, leading them to aggregate faster, which could explain why there is an increase in the number of blood clots in COVID patients. Also Read - COVID-19 antibodies, vaccines less effective against coronavirus variants: Study

Infection triggers genetic changes in platelets

To find out what might be going on, the researchers studied 41 COVID-19 patients hospitalized at University of Utah Hospital in Salt Lake City. Seventeen of these patients were in the ICU, including nine who were on ventilators. They compared blood from these patients with samples taken from healthy individuals who were matched for age and sex. Using differential gene analysis, the researchers saw that SARS-CoV-2, the virus that causes COVID-19, appears to trigger genetic changes in platelets. In laboratory studies, they studied platelet aggregation, an important component of blood clot formation, and saw that COVID-19 platelets aggregated more readily. They also noted that these changes significantly altered how platelets interacted with the immune system. This led them to conclude that this is what is most likely contributing to inflammation of the respiratory tract that may, in turn, result in more severe lung injury. Also Read - Corona passport: Not recommended but may be unavoidable, says WHO

Inflammation causes the genetic changes

Surprisingly, Campbell and his colleagues didn’t detect evidence of the virus in the vast majority of platelets, suggesting that it could be promoting the genetic changes within these cells indirectly. One possible mechanism is inflammation. In theory, inflammation caused by COVID-19 could affect megakaryocytes, the cells that produce platelets. As a result, critical genetic alterations are passed down from megakaryocytes to the platelets, which, in turn, make them hyperactive. Researchers say that there are genetic processes that they can target to prevent platelets from changing. If they can figure out how COVID-19 interacts with megakaryocytes or platelets, then they may be able to block that interaction and reduce someone’s risk of developing a blood clot.

Aspirin may prevent this hyperactivity

In test tube studies, the researchers found that pre-treating platelets from SARS-CoV-2 infected patients with aspirin did prevent this hyperactivity. These findings suggest aspirin may improve outcomes. However, researchers agree that further studies and clinical trials are needed to verify this. They also warn that patients must not use aspirin to treat themselves if they acquire this virus and instead said that they must consult their doctor. For now, Campbell warns against using aspirin to treat COVID-19 unless recommended by your physician.

(With inputs from Agencies)

Published : July 1, 2020 2:56 pm | Updated:July 2, 2020 6:37 am

Read Disclaimer

US considering pool testing for COVID-19: All you need to know about this new approach

Doctors’ Day 2020: Expert tips for patients and physicians to get along with each other

Facemask is not just a preventive tool: Humidity in masks can lessen COVID-19 severity too

Accurate and fast: Dogs can sniff out COVID-19 positive cases after only 4 days of training

Covid-19 was present in France in November 2019, suggests study

COVID-19 Live Updates: Cases in India surge to 10,838,194 while death toll reaches 1,55,080

Schizophrenia emerges as the second highest risk factor of COVID-19 mortality

About The health Site

Useful Links